Though the late-stage trial results showed an efficacy of 70% on average, up to 90% of people can be protected if a lower dose is administrated ahead of a full dose. AstraZeneca said the vaccine is highly effective. (PIC-UNI) AstraZeneca and the University of Oxford have said their jointly developed